IL-17 receptor A antigen binding proteins
AssigneeAmgen K-A, Inc.
InventorsJoel E. Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
Life of this patent
Estimating the term…
Abstract
Disclosed is an isolated human monoclonal antibody that specifically binds IL-17 Receptor A, or an IL-17 Receptor A binding fragment thereof, and inhibits IL-17A from binding and activating the receptor. The present disclosure also provides compositions and methods for treating diseases mediated by IL-17 Receptor A activation.
Claims5
An isolated human monoclonal antibody that specifically binds IL-17 Receptor A, or an IL-17 Receptor A binding fragment thereof, and inhibits IL-17A from binding and activating said receptor, which antibody comprises a light chain CDR1, CDR2, and CDR3 amino acid sequence of SEQ ID NO:224, SEQ ID NO:225, and SEQ ID NO:226, respectively, and a heavy chain CDR1, CDR2, and CDR3 amino acid sequence of SEQ ID NO:146, SEQ ID NO:147, and SEQ ID NO:148, respectively.
A method of treating psoriasis in a patient in need thereof, comprising administering to said patient a composition comprising a human monoclonal antibody that specifically binds IL-17 Receptor A, or an IL-17 Receptor A binding fragment thereof, and inhibits IL-17A from binding and activating said receptor, which antibody comprises a light chain CDR1, CDR2, and CDR3 amino acid sequence of SEQ ID NO:224, SEQ ID NO:225, and SEQ ID NO:226, respectively, and a heavy chain CDR1, CDR2, and CDR3 amino acid sequence of SEQ ID NO:146 SEQ ID NO:147 and SEQ ID NO:148 respectively.
Dependencies are inferred from the claim text.